about
EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is Dependent on KRAS Mutational Status in Colorectal Cancer Cells.Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer.Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial.The treatment of advanced gastric cancer: current strategies and future perspectives.Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology.SEOM Clinical Guideline of localized rectal cancer (2016).Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment.Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system.Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer.Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.Personalised Treatment in Gastric Cancer: Myth or Reality?Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.Selective approach for upper rectal cancer treatment: total mesorectal excision and preoperative chemoradiation are seldom necessary.Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines.Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors.Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and PharmacodynamicsParotid gland metastasis of a breast cancerExtending neoadjuvant chemotherapy in rectal cancerErratum to «Non-surgical treatment of localized rectal cancer is an experimental option»Non-surgical treatment of localized rectal cancer is an experimental optionNRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2-Amplified Gastric Cancer
P50
Q35674250-02B6B00F-D7E5-4D5B-9A05-3EB029BA130BQ36086845-9849A9A7-EC80-4C69-BC55-3D1D2E7FE030Q36413660-E2CDB3FD-4BEB-4C03-B460-E3ECDC072B72Q36858054-8528E5C7-53AE-4170-BED1-5784BCAC9BB2Q37210704-183642F6-F8E2-401E-8E70-2A46878C28E5Q37225594-AAF13004-4E49-4CC8-BC2D-F3B4D91D4FCAQ37475229-B3092702-6D38-490C-8A5B-8654C8FC1D33Q37665344-8FBFF033-63DC-4A99-8D70-62BA57D9DAB5Q37666259-98B54134-58DE-46DD-84BF-173F0326CE60Q38741222-FDACFF5A-D7D8-44BE-AA8B-ABF569B61158Q38760325-B57B1BE6-1435-4C82-BFCB-1509415BECFCQ38842137-B74C95FA-8C63-47D3-9321-271A43E6D901Q38876494-4A93DF26-4298-475A-81EA-7E66284CF07BQ40972888-4A5A5234-5BB1-43FF-BB2A-EF20D9C8BA9EQ43184357-A2C28EEC-0EEF-40D4-A5C1-18292E160F42Q46139159-843FE37A-D3B7-4D3F-9DD5-293A1D2E1C90Q50205188-2C7ABF4C-B390-4012-B123-27C1CEA9685BQ53159452-589C6148-EBE7-43CC-B217-E8F38991E96FQ58614732-71A8748F-6C7E-4E1B-AF52-E571ECC29858Q80226274-77BE36A7-D99A-417D-A2B3-8313FCF66E56Q85622293-6C0E6A85-D935-42BD-9861-5B76B9998359Q88409456-3500887F-7D60-457F-9C28-42FB413252DDQ89338385-68712874-060C-4026-BA00-3BA57670EAA0Q90029982-9E8B191F-127F-4F1F-8A52-FC92BC7A820C
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
S Roselló
@en
S Roselló
@nl
type
label
S Roselló
@en
S Roselló
@nl
prefLabel
S Roselló
@en
S Roselló
@nl
P31
P496
0000-0003-3915-4130